Benchmark Medical

Benchmark Medical was established in 2015 on Guangzhou International Bio Island, with R&D centers in both China and the United States. The company is committed to the development, production, and sales of cancer early screening and early diagnosis products using internationally advanced methylation high-throughput sequencing technology, as well as providing corresponding testing services. The founder, Dr. Fan Jianbing, is an internationally renowned expert in the field of genetic testing, listed on the 2021 "Top 2% of Scientists Worldwide - Lifetime Scientific Influence Ranking," with 30 years of experience in human genomics, gene chip, and high-throughput sequencing technology development. Benchmark Medical is a pioneer in China in applying ctDNA methylation high-throughput sequencing technology for early tumor detection, focusing on two main lines: "one tube of blood" and "one tube of urine," developing tests covering over 70% of high-incidence cancers including lung cancer, breast cancer, digestive system cancers, and urinary system cancers, spanning the entire process of early cancer screening, early diagnosis, recurrence monitoring, and companion diagnostics.